The global continuous bioprocessing technologies market is projected to grow from USD 4.8 billion in 2026 to USD 8.5 billion by 2031, driven by rising biologics demand, regulatory support, and the biopharmaceutical industry's shift from batch to continuous production. Key growth drivers include cost efficiency, improved quality, and faster time to market, though high capital investment and technical complexity remain challenges.

Alkermes announced positive top-line results from a phase I proof-of-concept study of ALKS 7290, an orexin 2 receptor agonist for ADHD treatment. The drug demonstrated dose-dependent, clinically meaningful improvements in ADHD symptoms with median AISRS score reductions of 14-19 points and was well tolerated with no serious adverse effects. Phase II studies are ongoing with data expected in 2027.

The global bioprocess automation market is projected to grow from USD 8.6 billion in 2025 to USD 22.2 billion by 2033, expanding at a CAGR of 12.8%. Growth is driven by rising demand for biologics, advances in AI and robotics, and pressure to improve manufacturing efficiency and regulatory compliance. Automation technologies enhance throughput, consistency, and cost-effectiveness while reducing errors and production time.

Novartis announced positive results from late-stage REMODEL-1/-2 studies showing remibrutinib, a BTK inhibitor, significantly reduced annualized relapse rates versus Aubagio in relapsing multiple sclerosis patients. The drug also reduced inflammatory brain lesions with a favorable safety profile. Novartis plans global regulatory filings and will present data at MSToronto2026. Shares gained 6% on the news.

Jazz Pharmaceuticals missed Q2 2026 EPS expectations ($5.71 vs. $6.04 estimate) due to $77 million in acquired IPR&D expenses, but beat revenue estimates at $1.21 billion. The company raised full-year 2026 revenue guidance to $4.60-$4.75 billion, driven by strong performance in its sleep franchise (Xywav up 13%), epilepsy business (Epidiolex up 16%), and oncology portfolio (up 32%). Despite the positive outlook, shares have underperformed the S&P 500 by 6.9% since the earnings report.

GSK announced it will begin a Phase III efficacy study of its mRNA-based seasonal flu vaccine in September 2026, following positive Phase II results showing higher immune responses than standard and high-dose flu vaccines. The vaccine uniquely targets both HA and NA antigens, unlike most existing flu vaccines. The FDA granted Fast Track designation to the candidate. Moderna's mFlusiva mRNA flu vaccine was recently approved by the FDA for adults 50+.

Teva Pharmaceutical has made a bid to acquire certain assets of BioXcel Therapeutics, including Igalmi (dexmedetomidine sublingual film) and the investigational BXCL501 formulation under FDA review for at-home treatment of acute agitation. Teva would pay $57.5 million upfront with up to $67.5 million in contingent payments. The acquisition aligns with Teva's neuroscience expansion strategy and Pivot to Growth initiative.

Repligen (RGEN) reported Q2 2026 adjusted EPS of 54 cents, beating the consensus estimate of 45 cents, with revenues of $204.1 million up 12% year-over-year. The company raised its full-year 2026 revenue guidance to $813-$835 million and EPS guidance to $2.03-$2.09. Stock has gained 27.7% since the earnings report and received a Zacks Rank #1 (Strong Buy) rating.

The global sterile bioprocess filtration market is projected to grow from USD 6.50 billion in 2025 to USD 31.33 billion by 2034, at a CAGR of 19.13%. Growth is driven by rising biopharmaceutical and vaccine demand, outsourcing to CMOs/CDMOs, and technological advancements. North America is expected to lead the market, with membrane filters dominating the product segment.

Bio-Techne shares surged 20% after Merck KGaA announced a $73-per-share cash acquisition offer. The deal comes one week after activist investor Ananym Capital Management built a stake and pushed for a sale. Trading volume reached 51.3M shares, significantly above average. Merck KGaA expects to achieve over $150 million in annual cost synergies within three years.

The global single-use bioprocessing market is expected to grow from USD 30.12 billion in 2025 to USD 122.92 billion by 2035 at a CAGR of 15.1%. Driven by technological breakthroughs in bioreactor scalability (up to 6,000L), 40-50% CAPEX reductions, and FDA approvals of 16 single-use-manufactured biologics in 2024, the market is becoming the standard for commercial biomanufacturing. Major players are expanding capacity significantly, with CDMOs like WuXi Biologics managing substantial backlogs.

The global continuous bioprocessing market is projected to grow from USD 319.77 million in 2025 to USD 2,331.98 million by 2035 at a CAGR of 21.98%. Driven by demand for biosimilars and complex biologics, manufacturers are shifting from traditional fed-batch to continuous methods, achieving 50% cost reductions and significant sustainability improvements. North America leads with 39% market share, while Asia Pacific rapidly expands capacity. Major pharmaceutical and biotech companies are deploying billions in capital investments to modernize manufacturing infrastructure.